{"id":13254,"date":"2017-11-24T15:30:08","date_gmt":"2017-11-24T14:30:08","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=13254"},"modified":"2017-11-24T15:32:09","modified_gmt":"2017-11-24T14:32:09","slug":"kreftforeningsmidler-til-k2-forskere","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2017\/11\/24\/kreftforeningsmidler-til-k2-forskere\/","title":{"rendered":"[:no]Kreftforeningsmidler til K2-forskere[:en]The Norwegian Cancer Society funding for K2 researchers[:]"},"content":{"rendered":"

[:no]Kreftforeningen delte ut 170 millioner i sin Open Call 2017, Universitetet i Bergen fikk 54,7 millioner av disse, hvorav 4 prosjekter fra K2<\/strong> ble tildelt i alt 34,6 millioner<\/strong>! I tillegg fikk Stian Knappskog en ekstra honn\u00f8rpris som \u00abProsjekt med best brukermedvirkning\u00bb, det kommer vi tilbake til.<\/p>\n

\"\"<\/a>

Glade UiB kreftflaggskipforskere flankert av rektor, sykehusdirekt\u00f8r og dekan.<\/p><\/div>\n

Tildelingen ble offentliggjort p\u00e5 en flott seremoni i Bikuben mandag 6.11, der Kreftforeningens generalsekret\u00e6r Anne Lise Ryel bekreftet at disse midlene ble utdelt til landets ledende kreftforskningsmilj\u00f8<\/strong>. Universitetsdirekt\u00f8r Dag Rune Olsen var ikke snauere: han konkluderte med at selv om norsk forskning tradisjonelt er lavm\u00e6lt og tuftet p\u00e5 hardt og systematisk arbeid s\u00e5 skal man sette s\u00e5pass \u00abh\u00e5ret\u00bb m\u00e5l at Bergensk forskning f\u00e5r global impakt!<\/p>\n

Dekan ved Medisinsk fakultet Per Bakke understreket viktighet av at disse midlene (og derav forskning) skulle komme pasientene til gode. Brukerperspektivet var ogs\u00e5 tydelig understreket ved at Kreftforeningen i denne runden hadde med brukerrepresentanter i panelet n\u00e5r s\u00f8knadene ble vurdert. En av disse representantene, Bamse Mork Knudsen, bekreftet at brukermedvirkning styrker tilliten til forskningen og at selv om ogs\u00e5 de var litt usikre p\u00e5 sin rolle i prosessen s\u00e5 skulle ikke forskere n\u00f8le med \u00e5 ta dem ibruk: \u00abJust do it!\u00bb<\/p>\n

\"\"<\/a><\/p>\n

En som faktisk hadde f\u00e5tt dette s\u00e5 godt til at han ogs\u00e5 fikk den f\u00f8rste Kreftforeningens<\/strong> Brukermedvirkningspris<\/strong> var Stian Knapskog. <\/strong>Han fikk tildelt 8,9 millioner<\/strong> til sitt prosjekt \u00abUncovering the genetic causes of resistance to chemotherapy in breast cancer\u00bb <\/em>og forklarer deres brukerfokus slik: \u00abI brystkreftmilj\u00f8et har vi, s\u00e6rlig ved klinikarane Per E L\u00f8nning og Hans P. Eikesdal, hatt eit langvarig og godt samarbeid med brystkreftforeningen, b\u00e5de nasjonalt, og lokalt i Bergen. Det vi har gjort ved \u00e5rets s\u00f8knader fr\u00e5 milj\u00f8et, og ved nye prosjekt som blir starta, er at vi formaliserer dette samarbeidet ved \u00e5 etablere eit bruker-advisory board. Her er representantane oppnemnt av brystkreftforeningen, og boardet vil m\u00f8tes 2 gonger i \u00e5ret for \u00e5 bli oppdatert p\u00e5 dei vitenskapelige prosjektene, samt \u00e5 komme med dei r\u00e5d og innspel dei m\u00e5tte ha til oss, fr\u00e5 eit brukar-perspektiv.\u00bb Dette til inspirasjon for oss andre!<\/p>\n

Per L\u00f8nning<\/strong> fikk 8,5 millioner <\/strong>til prosjektet \u00abGenome-directed breast cancer therapy<\/em>\u00bb. Disse midlene kommer fra \u00e5rets \u00abKrafttak mot kreft\u00bb-innsamling Forskningsprogrammet best\u00e5r av to kliniske studier der m\u00e5lsettingen er \u00e5 finne fram til mer m\u00e5lrettet terapi for pasienter med prim\u00e6r brystkreft og pasienter med metastatisk brystkreftsykdom.<\/p>\n

En viktig m\u00e5lsetting er \u00e5 designe nye m\u00e5lrettete cellegiftregimer for pasienter med svulster som er forbundet med d\u00e5rlig prognose. I disse tilfellene gis et nytt cellegiftregime, eventuelt et m\u00e5lrettet medikament.<\/p>\n

Camilla Krakstad<\/strong> fikk 9,2 millioner <\/strong>til prosjektet \u00abIndividualized treatment of endometrial cancer<\/em>\u00bb. Dette var det eneste av alle Kreftforeningens tildelinger i \u00e5r som gikk til underlivskreft. Krakstads prosjekt inneb\u00e6rer omfattende kartlegging av forandringer b\u00e5de i prim\u00e6r- og spredningssvulster. Nye identifiserte m\u00e5l for behandling i spredningssvulstene vil bli unders\u00f8kt videre i avanserte sykdomsmodeller der effekten av nye medikamenter testes ut. Funnene fra testingen vil gi bedre grunnlag for \u00e5 velge medikament for videre utpr\u00f8vende pasientbehandling. En klinisk studie av nye mark\u00f8rer vil unders\u00f8ke om disse kan benyttes i daglig rutine for \u00e5 velge optimal kirurgisk behandling for pasientene. Det overordnede m\u00e5let er \u00e5 finne frem til bedre og mer individuelt tilpassete former for behandling ved livmorkreft.<\/p>\n

Bj\u00f8rn Tore Giertsen <\/strong>fortalte f\u00f8rst om hvordan han hadde brukt alle de forrige midler fra Kreftforeningen, f\u00f8r han mottok tildelingen p\u00e5 8 millioner<\/strong> fra \u00e5rets \u00abKraftak mot kreft\u00bb- innsamling til prosjektet \u00abDevelopment of novel combined CSF 1R\/FLT3-targeted therapy in acute leukemia<\/em>\u00bb. Prosjektet vil\u00a0utforske biologien til reseptorene FLT3 og CSF1R\u00a0ved akutt leukemi, to signaleringsenzymer som er direkte eller indirekte p\u00e5virket av mutasjoner i kreftcellenes signalsystemer. \u00a0Slike mutasjoner finner vi hos 50% av alle leukemipasientene. Fem \u00e5rs overlevelse ved akutt myelogen leukemi er mindre enn 20% etter fem \u00e5r. M\u00e5let er \u00e5 utvikle ny ma\u030alrettet behandling mot CSF1R og FLT3 ved akutt leukemi, og bruke nye m\u00e5lemetoder for enkeltvise leukemiceller og immunceller i form av massecytometri. Disse massecytometriske metodene vil bli brukt for \u00e5 m\u00e5le interaksjon mellom tumor og vert, og bestemme hvilke pasienter som responderer f\u00f8r eller kort etter behandlingsstart.<\/p>\n

Hjertelig gratulerer fra alle oss i K2!<\/p>\n

Jone Trovik[:en]The Norwegian Cancer Society awarded 170 million through their Open Call 2017, the University of Bergen received 54,7 million whereas 4 projects from K2<\/strong> were awarded in total 34,6 million<\/strong>! In addition Stian Knappskog received a supplementary honorary prize as \u00abProject with best user contribution\u00bb, see more specific below.<\/p>\n

\"\"<\/a>

Happy UiB Cancer Flag-ship researchers, Rector and Secretary General, flanked by Dean and Hospital Director.<\/p><\/div>\n

The award ceremony took place at Bikuben Monday 6th<\/sup> of November, where the Norwegian cancer Society\u2019s secretary general Anne Lise Ryel confirmed that these funding were awarded to the leading Norwegian cancer research environment<\/strong>. University rector Dag Rune Olsen was not less bold: Although Norwegian research traditionally is rather hushed, by continuing our hard, systematic work Norwegian research may well achieve global impact!<\/p>\n

Dean of the medical Faculty Per Bakke underlined that these funding (and the resulting research) should benefit the patients! The user perspective was solidly based this year: the Cancer Society had incorporated user representatives in their evaluation process. One of these representatives, Bamse Mork Knudsen, confirmed that user contribution strengthen the legitimacy and trust of research. Although they themselves were somewhat uncertain of their specific role in the process, he urged researcher to not hesitate in incorporating user contributors: \u00abJust do it!\u00bb<\/p>\n

\"\"<\/a><\/p>\n

One which had incorporated this in such exemplary fashion that he was awarded the first \u00ab Cancer Society User Contribution Prize\u00bb, was Stian Knapskog. <\/strong>He was awarded 8,9 million <\/strong>for his project \u00abUncovering the genetic causes of resistance to chemotherapy in breast cancer\u00bb <\/em>and explains the user focus in this way: \u00abWithin the research environment of breast cancer we have, especially the clinicians Per E L\u00f8nning and Hans P. Eikesdal, a longstanding good cooperation with the Breast Cancer (patient) Society, both nationally and locally in Bergen. In this year\u2019s application, and with future projects, we have formalized this contact by establishing a user-advisory board. The representatives have been appointed by the Breast Cancer Society, and the board will meet biannually, receive updates regarding the ongoing projects and contribute with advice\/inputs for the researchers.\u00bb May this be an inspiration for all of us!<\/p>\n

Per L\u00f8nning<\/strong> was awarded 8,5 millioner <\/strong>for the project \u00abGenome-directed breast cancer therapy<\/em>\u00bb. This funding is part of this year\u2019s \u00abCollective effort against cancer\u00bb fund rising. The research program consists of two clinical studies whose aim is to find more targeted therapy for patients with primary breast cancer and patients with metastatic breast cancer disease.<\/p>\n

An important goal is to design new targeted chemotherapy regimens for patients with tumors associated with poor prognosis. For these patients, a new chemotherapy regimen, possibly a targeted drug, is given.<\/strong><\/p>\n

Camilla Krakstad<\/strong> was awarded 9,2 million <\/strong>with her project \u00abIndividualized treatment of endometrial cancer<\/em>\u00bb. This was the only Cancer Society funding awarded for gynaecological cancer research this year. Krakstad\u2019s project involves extensive mapping of changes in both primary and metastatic tumors. New identified targets for treatment in the metastatic tumors will be investigated in advanced disease models where the effect of new drugs is tested. The findings from these investigations will provide a better basis for selecting medication for further clinical testing. A clinical study of new markers will investigate whether these can be used in daily routine to choose optimal surgical treatment for patients. The overall goal is to find better and more individually tailored treatment for uterine cancer.<\/p>\n

Bj\u00f8rn Tore Giertsen <\/strong>first described how he had used all former grants he had recived from the Cancer Society. This year he was awarded 8 million<\/strong> from the \u00abCollective effort against cancer\u00bb fund rising for his project \u00abDevelopment of novel combined CSF 1R\/FLT3-targeted therapy in acute leukemia<\/em>\u00bb. Acute myeloid leukemia is an aggressive hematopoietic stem cell disease with less than 20% overall survival after five years. Signal transduction pathways, like receptor tyrosine kinases, are mutated in more than half of the patients. The project will explore the biology of receptor tyrosine kinases CSF1R and FLT3 in acute\u00a0leukaemia, and develop CSF1R\/FLT3 targeted therapy for acute\u00a0leukaemia along with biomarkers\u00a0for early detection of therapy non-responders. Mass cytometry will be used to monitor single cell perturbations in intracellular signaling systems combined with immune modulation in blood and bone marrow.<\/p>\n

Heartily congratulations from all of us in K2!<\/p>\n

Jone Trovik[:]<\/p>\n","protected":false},"excerpt":{"rendered":"

[:no]Kreftforeningen delte ut 170 millioner i sin Open Call 2017, Universitetet i Bergen fikk 54,7 millioner av disse, hvorav 4 prosjekter fra K2 ble tildelt i alt 34,6 millioner! I tillegg fikk Stian Knappskog en ekstra honn\u00f8rpris som \u00abProsjekt med…<\/p>\n

Read more →<\/a><\/p>\n","protected":false},"author":3699,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-13254","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/13254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/3699"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=13254"}],"version-history":[{"count":3,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/13254\/revisions"}],"predecessor-version":[{"id":13280,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/13254\/revisions\/13280"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=13254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=13254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=13254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}